Whitestar can deal with even the hardest nuclei

Article

Microincision cataract surgery (MICS) with the Whitestar ICE and CASE systems (AMO) can be performed safely and effectively even in the hardest nuclei, according to a Turkish study.

Microincision cataract surgery (MICS) with the Whitestar ICE and CASE systems (AMO) can be performed safely and effectively even in the hardest nuclei, according to a Turkish study.

Hasan Oguzhan and colleagues from the Dr Sadi Konuk Education and Research Hospital, Istanbul, Turkey performed MICS on 20 eyes (17 patients) using the Whitestar surgical system with ICE and CASE settings. Patients were selected according to their nucleus hardness (grade 3 – 4) and were examined for intraoperative complications, mean phaco time, total phaco %, effective phaco time (EPT), endothelial cell loss, postoperative corneal oedema and mean uncorrected and best corrected visual acuity.

The mean phaco time, total phaco % and EPT were one minute 24 seconds, 4.8% and 3.22 seconds, respectively. The mean preoperative and postoperative endothelial cell counts and percentage endothelial cell loss were 2 376, 2 253, and 5.2%, respectively. The mean early (within three days) postoperative uncorrected visual acuity and late postoperative best corrected visual acuity were 0.6 and 0.9 on the Snellen chart, respectively. There were no complications and surgery was performed safely in even the hardest nuclei.

It was the conclusion of the authors that bimanual MICS using the Whitestar ICE and CASE systems is both safe and effective even in the hardest nuclei.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
© 2025 MJH Life Sciences

All rights reserved.